Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q4 2019 · 10-K
Revenue$35.08M$35.08M+21.6% vs Q4 2018 Net Income-$57.92M-$57.92MN/M vs Q4 2018 EPS Diluted-$0.65-$0.65N/M vs Q4 2018 Gross Profit$19,209,000+11.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$26,977,000N/M Free Cash Flowderived-$30,880,000N/M Margins · derivedGross margin54.8%−5.1 pt vs Q4 2018
Operating margin-169.2%+8.7 pt vs Q4 2018
Net margin-165.1%+6.7 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 2, 2020 · 62 d after period end